EGFR and non-small cell lung carcinoma: Building on the safety and efficacy findings explored in a prior study involving 20 patients with NSCLC as part of the CHRYSALIS trial [45], the phase 3 PAPILLON trial was conducted to evaluate the efficacy and safety of amivantamab in combination with carboplatin–pemetrexed in comparison to standard chemotherapy alone as a first-line treatment for patients (n = 308) with advanced NSCLC with EGFR exon 20 insertions [40].